Steve Bryson, PhD, science writer —

Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.

Articles by Steve Bryson

Diabetes med metformin studied as Cushing’s treatment

Metformin, a medicine used mostly to treat type 2 diabetes, eased the signs of Cushing’s disease in cells and in a mouse model, a study showed. “These findings suggest metformin as a potential drug for the treatment of Cushing’s disease,” researchers wrote in the study, “Metformin…

Woman with Cushing’s seen with rare digestive tract perforation

A woman with Cushing’s syndrome developed an ulcer that caused a gastrointestinal perforation, or a hole in the digestive tract, according to a case study. Because she had no established risk factors for such a complication, researchers suggested prolonged exposure to high levels of cortisol, or hypercortisolism, may have contributed…

Surprising data found in study on Cushing’s disease in children

More boys were diagnosed with Cushing’s disease before puberty than were girls, according to an examination of medical records of children and adolescent patients across Turkey. These findings contrast with observations made in adults, in whom women are diagnosed with Cushing’s far more often than men. The researchers noted,…

Low-grade inflammation persists after removing tumors

Low-grade inflammation persisted in people with Cushing’s syndrome one year after surgery to remove disease-causing tumors that led to excess cortisol, the hallmark of the condition, a recent study revealed. High levels of inflammatory markers were associated significantly with post-surgical obesity, high blood sugar levels, and worse long-term muscle function,…

Approved Therapy Recorlev Now Wins FDA Orphan-drug Exclusivity

The U.S. Food and Drug Administration (FDA) has granted Xeris Pharmaceuticals orphan-drug exclusivity for Recorlev (levoketoconazole), its approved treatment for adults with endogenous Cushing’s syndrome. Orphan-drug exclusivity provides the company — which recently acquired the therapy’s developer, Strongbridge Biopharma — seven years of marketing exclusivity for Recorlev…

Study Examines Role of Hormone in Subclinical Hypercortisolism

The hormone aldosterone may contribute to high blood pressure in people with subclinical hypercortisolism — those who have high levels of cortisol due to tumors in the adrenal glands, but do not have overt symptoms of Cushing’s syndrome. Aldosterone, excessively produced and released by the adrenal glands in these patients,…